A. Vogel AG
🇨ðŸ‡Switzerland
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Private
- Established
- 1963-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.avogel-company.ch
Eschscholzia Study
Phase 3
Not yet recruiting
- Conditions
- Sleep
- Interventions
- Drug: Eschscholzia tabletsDrug: Placebo Tablets
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 100
- Registration Number
- NCT06795776
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex, Sofia, Bulgaria
Mental Balance Study
Not Applicable
Completed
- Conditions
- Work Related StressMental Health Wellness 1
- Interventions
- Dietary Supplement: Re-Focus "Verum" TabletsDietary Supplement: Re-Focus "Placebo" Tablets
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 36
- Registration Number
- NCT05757050
- Locations
- 🇬🇧
Northumbria University, Newcastle Upon Tyne, Tyne & Wear, United Kingdom
Sleep Well Observation Study
Not Applicable
Completed
- Conditions
- Sleep Disturbance
- Interventions
- Dietary Supplement: Sleep Well Sachet
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 50
- Registration Number
- NCT05748574
- Locations
- 🇩🇪
daacro GmbH & Co. KG, Trier, Rheinland-Pfalz, Germany
Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections
Phase 4
Completed
- Conditions
- Respiratory Tract InfectionsCommon Cold
- Interventions
- Drug: Echinaforce Chewable tablets
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 122
- Registration Number
- NCT05002179
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex EOOD, Sofia, Bulgaria
Echinaforce COVID-19 Shedding Study
Phase 4
Terminated
- Conditions
- COVID-19 Respiratory InfectionSARS-CoV2 Infection
- Interventions
- Drug: Echinaforce Forte tabletsDrug: Echinaforce Chewable tabletsDrug: Echinaforce tincture
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 40
- Registration Number
- NCT04999098
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex EOOD, Sofia, Bulgaria
Study to Assess Safety and Efficacy of Nephrosolid Tbs to Stimulate Urinary Output in Non-patient Volunteers
Phase 3
Completed
- Conditions
- Urine Specimen Collection
- Interventions
- Drug: Nephrosolid tablets
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 66
- Registration Number
- NCT04338477
- Locations
- 🇨ðŸ‡
Privat practice of Dr. med. Bruno Haug, Medizinisches Zentrum Arbon, Arbon, Thurgau, Switzerland
🇨ðŸ‡Private Practice Dr. med Bernhard Waelti, Freidorf, Thurgau, Switzerland
Safety and Efficacy of the Sore Throat Lozenges to Treat Acute Sore Throats
Phase 4
Completed
- Conditions
- TonsillopharyngitisRespiratory Tract Infection Viral
- Interventions
- Drug: A. Vogels Sore Throat lozenges
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 74
- Registration Number
- NCT04139681
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex EOOD, Sofia, Bulgaria
Superiority of Newly Developed Over Basic Echinacea Formulations for the Treatment of Respiratory Tract Infections
Phase 2
Completed
- Conditions
- Respiratory Tract Infections
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 246
- Registration Number
- NCT03812900
- Locations
- 🇨ðŸ‡
Cantonal Hospital St. Gallen, Saint Gallen, Switzerland
Echinaforce Junior Bioavailability Trial
Phase 4
Withdrawn
- Conditions
- Common Cold
- Interventions
- Drug: Echinaforce junior
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- A. Vogel AG
- Registration Number
- NCT03070314
- Locations
- 🇨ðŸ‡
University Children's Hospital (UZH-UCH), Infectiology, University of Zurich, Zurich, Switzerland
Echinacea Junior vs Vitamin C in Children 4-12 Years Old
Phase 3
Completed
- Conditions
- Respiratory Tract Infection Viral
- Interventions
- Drug: Echinaforce
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 203
- Registration Number
- NCT02971384
- Locations
- 🇨ðŸ‡
Dr. med. Mercedes Ogal, Brunnen, Switzerland
© Copyright 2025. All Rights Reserved by MedPath